Mercy BioAnalytics, Inc.
Dawn Mattoon has extensive work experience in the biotech industry, starting as a Scientist in Protometrix in 2004, and advancing to Senior Scientist, R&D Manager, Director of Program Management, Senior Director of Global Program & Portfolio Management, and Senior Director of Strategy while at Life Technologies from 2004 to 2014. In 2014, they joined Cell Signaling Technology (CST) as Vice President of Product Development and later joined Quanterix as Senior Vice President of Strategic Marketing & Assay Technologies in 2018. In 2022, they became the Chief Operating Officer of Mercy BioAnalytics, and one year later, was promoted to Chief Executive Officer.
Dawn Mattoon received their Bachelor of Arts degree in Biology from Bard College in 1994. From 1997 to 2001, they pursued their Ph.D. in Genetics from Yale University.
Mercy BioAnalytics, Inc.
Mercy BioAnalytics is a biotechnology company that aims to improve and save the lives of people through the early detection of cancer.It has developed a process that uses nano-particles that are extraordinarily abundant in blood and carry information about their parent cell – known as extracellular vesicles, or EVs – to detect stage I cancer.Paul Blavin and Joseph Sedlak founded the Natick, Massachusetts-based company in 2018.